Abstract Virus-specific CD8 +
Introduction
The SIV-infected rhesus macaque has long been an important animal model for HIV infections in humans. This model allows researchers to answer questions regarding the early events after infection, viral variation, disease pathogenesis, and to test new vaccine strategies. Having the ability to manipulate variables like viral strain, dose, and route of infection allows scientists to precisely monitor the immune response to SIV. However, despite intensive study, we still do not understand what constitutes an efficacious cytotoxic T-lymphocyte (CTL) response. Since CTL are selected and educated based on the MHC present in an individual, and since different MHC alleles are able to bind different populations of peptides, understanding the MHC alleles and the SIV-derived peptides they present is necessary to understand why some genotypes are better able to control SIV infection. Control of SIV viral replication may be due to differences in the particular peptides bound or properties of the CTL engendered by MHC alleles in particular genotypes.
Several lines of evidence indicate that CTL are responsible for control of HIV/SIV viral replication. Depletion of CD8 + lymphocytes in SIV-infected macaques results in increased viral loads (Matano et al. 1998; Jin et al. 1999; Schmitz et al. 1999; Metzner et al. 2000; Alexander et al. 2001) . The appearance of virus-specific CTL is concurrent with the decline of peak viremia (Yasutomi et al. 1993; Borrow et al. 1994; Koup et al. 1994; Reimann et al. 1994; Ogg et al. 1998) . Additionally, it has been established that specific MHC class I alleles are associated with either slow or rapid disease progression (Klein et al. 1995; Kaslow et al. 1996; McNeil et al. 1996; Carrington et al. 1999; Hendel et al. 1999; Migueles et al. 2000; Kaslow et al. 2001; Tang et al. 2002; Yant et al. 2006; Loffredo et al. 2007b) . Finally, it is well documented that CTL exert strong enough selective pressure on immunodeficiency viruses sufficient to drive variation both inside and outside the epitopes they target (Phillips et al. 1991; Wolinsky et al. 1996; Borrow et al. 1997; Goulder et al. 1997; Price et al. 1997; Mortara et al. 1998; Van Baalen et al. 1998; Evans et al. 1999; Soudeyns et al. 1999; Wilson et al. 1999; Allen et al. 2000; Chen et al. 2000; Barouch et al. 2002 Barouch et al. , 2003 O'Connor et al. 2002; Vogel et al. 2002; Peyerl et al. 2003; Friedrich et al. 2004a, b) . It is therefore critical to characterize these CTL responses and the MHC class I molecules that restrict them.
To date, five Macaca Mulatta (Mamu) class I alleles (Mamu-A1*001:01, -A1*002:01, -A1*011:01, -B*017:01, and -B*008:01) have been thoroughly characterized with regard to their peptide-binding motifs and the SIV-derived peptides they bind (Allen et al. 2001; Mothe et al. 2002; Loffredo et al. 2004; Sette et al. 2005; Loffredo et al. 2009 ). Another allele, Mamu-B*001:01, was shown not to be involved in restricting epitopes derived from SIV mac 239 (Loffredo et al. 2005) . Taking into account the fact that macaques can express between four and 12 different MHC class I alleles (Boyson et al. 1996; Urvater et al. 2000) , the identification and study of additional alleles enhances the animal model's utility.
To fully characterize an MHC class I allele involves a combination of several different approaches. Typically, sequencing of naturally occurring ligands combined with identification of optimal T-cell epitopes leads to a preliminary motif that can be further refined with peptide-binding assays using purified MHC (Van Bleek and Nathenson 1990; Falk et al. 1991; Kast et al. 1994; Kubo et al. 1994; Rammensee et al. 1995; Sidney et al. 2000) . A comprehensive analysis requires knowledge of secondary interactions to best identify the peptides that will be bound in vivo (Ruppert et al. 1993; Kondo et al. 1995; Sidney et al. 1996) . Once a peptidebinding motif is determined for a particular MHC class I allele, candidate epitopes can be efficiently identified and then tested for immunogenicity utilizing a rapid screening method, such as IFN-γ ELISPOT using PBMC from SIVinfected macaques. Those epitopes that elicit a response can be utilized to manufacture fluorescently labeled tetrameric peptide-MHC complexes (Altman et al. 1996; Kuroda et al. 1998; Ogg et al. 1998 ). These tetramers serve as reagents for immune monitoring in future experiments utilizing animals with defined MHC class I alleles. Additionally, the regions of the virus that contain these epitopes can be monitored for viral evolution and escape, and also be evaluated as candidates for inclusion in future vaccines. Of the six characterized alleles, two (B*008:01 and B*017:01) often need to be excluded from vaccine studies due to correlation with spontaneous SIV control. Thus, characterization of additional Mamu MHC I alleles is needed to add to the cohort of MHC I characterized rhesus macaques for use in vaccine studies.
Mamu-A1*007:01 (formerly known as A*07 before being renamed by the Comparative MHC Nomenclature Committee) has been determined by polymerase chain reactionsequence-specific priming (PCR-SSP) to be present in 5.27% (55 of 1,165) of the macaques at the Wisconsin National Primate Research Center (WNPRC) colony, 10.6% at the Oregon National Primate Research Center (eight of 75), and total frequency of 5.08% of all rhesus macaques tested. This allele is present in five of 27 SIV mac 239-infected elite controller (EC) animals in our cohort. The contribution of Mamu-A1*007:01 to viral control is not known. We sought to define the peptide-binding motif of Mamu-A1*007:01 and establish the epitopic breadth in SIV-infected Mamu-A1*007:01-positive macaques.
The Mamu-A1*007:01 group of alleles in Indian rhesus macaques contains three known subtypes (:01, :02, and :03) (IPD Database, http://www.ebi.ac.uk/cgi-bin/ipd/mhc/get_ nomenclature.cgi?Mamu-A1). Additionally, Otting et al. (2007) described a related allele (A1*007:04) in Chinese rhesus macaques and Genbank lists yet another Chinese allele (A1*007:06, accession number EU334697). Recently, Naruse et al. (2010) and Otting et al. (2011) described two more related alleles in Burmese rhesus macaques (subtypes :02-like and :05, respectively). The amino acid differences between the various MHC class I subtypes might affect peptide binding (Supplemental Figure 1) . With the exception of a single animal, all of the animals that made Mamu-A1*007:01-restricted CTL responses in this study had subtype :01. Rh2001 appears to be of mixed origin and has the A1*007:02-like allele subtype.
We defined the Mamu-A1*007:01-binding motif, generated potential SIV-derived peptide binders, and tested them in Mamu-A1*007:01-positive macaques that had either been vaccinated with SIV mac 239 sequences or challenged with SIV mac 239. We found six novel epitopes from Pol, Vpr, Vif, and Gag that bind Mamu-A1*007:01. Two of these were previously used in studies detailing the kinetics of epitope presentation: Pol 782-789 YL8 and Vpr 45-55 NL11 (Sacha et al. 2007 (Sacha et al. , 2010 . CTL responses against four of these epitopes selected for viral variants are consistent with immunologic escape. The other two epitopes were derived from highly conserved regions of SIV; we did not detect viral variation despite robust responses against these regions. This result is intriguing as it indicates these regions might be under functional or structural constraints. Responses directed against these regions might be particularly effective at controlling SIV replication. Together, our data support a potential role for the Mamu-A1*007 allele in the immune response against SIV.
Materials and methods

Animals, viruses, and vaccinations
The Indian rhesus macaques (Macaca mulatta) used in this study were from the Wisconsin National Primate Research Center colony. We identified them as Mamu-A1*007 + by PCR-SSP using conditions as previously described (Kaizu et al. 2007 ). The primers used to amplify Mamu-A1*007 are as follows: forward=(GGG TGC GGC GGA GCA GA) and reverse=(CAC GAT GGG AAT GGT GGA CTC). The animals were cared for in accordance with the regulations and guidelines of the University of Wisconsin Institutional Animal Care and Use Committee.
See Supplemental Table 1 for a list of animals, vaccinations, and infecting viruses.
Peptide synthesis and positional scanning combinatorial library Peptides for screening were purchased as crude or purified material from Genscript (Piscataway, NJ, USA), A and A EEHDKYHSNVKELVF  EF15  EEHDKYHSN  EN9  EHDKYHSNV  EV9  HDKYHSNVK  HK9  DKYHSNVKE  DE9  KYHSNVKEL  KL9  YHSNVKELV  YV9  HSNVKELVF (Ruppert et al. 1993) . Peptides synthesized for use as radiolabeled ligands were synthesized by A and A Labs and purified to >95% homogeneity by reversed-phase HPLC. Purity of these peptides was determined using analytical reversed-phase HPLC and amino acid analysis, sequencing, and/or mass spectrometry. Peptides were radiolabeled with the chloramine T method . Lyophilized peptides were resuspended at 4-20 mg/ml in 100% DMSO, then diluted to required concentrations in PBS+0.05% (v/v) Nonidet P-40 (Fluka Biochemika, Buchs, Switzerland). SIV peptides were derived from the SIV mac 239 sequence, GenBank accession no. M33262 (Kestler et al. 1990 ).
The positional scanning combinatorial library (PSCL) was synthesized as previously described (Pinilla et al. 1992; Sidney et al. 2008a) . Each pool in the library contains 9-mer peptides with one fixed residue at a single position. With each of the 20 naturally occurring residues represented at each position along the 9-mer backbone, the entire library consisted of 180 peptide mixtures.
Mamu-A1*007:01 peptide-binding motif from endogenous ligands
We generated soluble Mamu-A1*007:01 by deletion of the transmembrane and cytosolic domains. The construct was transfected into 721.221 cell lines and stable, secreting, clones were selected for expansion into a bioreactor. Approximately 35 mg of sMamu-A1*007:01 was produced and purified using antibody affinity chromatography. Peptide ligands were eluted using an acid boil and separated from the complex using a 3-kDa cut-off filter. Ten percent of the peptide pool was subjected to Edman degradation sequencing to determine a peptide-binding motif. The remainder of the peptides was resolved into approximately 40 fractions using reversed-phase HPLC. HPLC fractions were then analyzed on an ESI QTOF mass spectrometer to generate MS ion maps (AB SCIEX, Foster City, CA, USA). Abundant ions were then fragmented and analyzed using MASCOT to determine sequence (Matrix Science, London, UK).
MHC purification and peptide binding assays MHC class I purification was performed using affinity chromatography as previously described Loffredo et al. 2009 ). Mamu-A1*007:01 molecules were purified from cell lysates of stable membrane-bound MHC class I 721.221 transfectants using the anti-HLA class I (A, B, and C) antibody W6/32 (Barnstable et al. 1978) . Protein purity, concentration, and depletion efficiency steps were monitored by SDS-PAGE.
Quantitative assays for the ability of peptide to bind to detergent-solubilized MHC class I molecules were based on the competitive inhibition of binding of a high-affinity radiolabeled standard probe peptide and performed as detailed previously Loffredo et al. 2009 ). Peptides were tested at six different concentrations covering a 100,000-fold dose range in three or more independent assays. The radio-labeled peptide used for the A1*007:01 assays was the SIV Pol [782] [783] [784] [785] [786] [787] [788] [789] (Cheng and Prusoff 1973; Gulukota et al. 1997) . In each experiment, a titration of the unlabeled version of the radiolabeled probe was tested as a positive control for inhibition.
Bioinformatic analysis
Analysis of the PSCL data was performed as described previously (Sidney et al. 2008a; Loffredo et al. 2009 ). Briefly, IC 50 nM values for each mixture were standardized as a ratio to the geometric mean IC 50 nM value of the entire set of 180 mixtures, and then normalized at each position so that the value associated with optimal binding at each position corresponds to 1. For each position, an average (geometric) relative binding affinity (ARB) was calculated, and then the ratio of the ARB for the entire library to the ARB for each position was derived. We have denominated this ratio, which describes the factor by which the normalized geometric average binding affinity associated with all 20 residues at a specified position differs from that of the average affinity of the entire library, as the specificity factor (SF). As calculated, positions with the highest specificity will have the highest SF value. Primary anchor positions were then defined as those with an SF≥2.4. This criterion identifies positions where the majority of residues are associated with significant decreases in binding capacity. Preferred residues at the primary anchor positions have been defined as those with ARB values within 5-fold of the optimal residue, and tolerated residues as those with an ARB in the 5-25-fold range of the optimal residue. Secondary anchor designations are based on the standard deviation (SD) of residue specific values at each position. Dominant secondary anchor positions were defined as those where the SD was >3 and the SF <2.4, as well as positions associated with an SD >2 if the SF is between 1.5 and 2.4.
Weak secondary anchors have been defined as positions associated with a SD between 2.5 and 3, with an SF <1.5, or an SF in the 1.5-2.4 range with an SD <2.
To identify predicted binders, all possible 9-mer peptides in SIV sequences were scored using the matrix values derived from the PSCL analysis as described previously (Sidney et al. , 2008a Loffredo et al. 2009 ). The final score for each peptide represents the product of the corresponding matrix values for each peptide residueposition pair. Peptides of 8, 10, or 11 residues in length were also selected using the combinatorial library as described previously ). Briefly, 8-mers were selected by scoring residues 1-7 with the corresponding residues in the 9-mer matrix, and the C terminus was scored using the corresponding 9-mer Cterminal value. Similarly, for 10-and 11-mer peptides, residues 1-8 were scored using the corresponding residues of the 9-mer matrix, and the C terminus with the 9-mer Cterminal residues. Peptides scoring among the top 1.5% (n= 50) for each size were selected.
IFN-γ ELISPOT assay
We performed ELISPOT assays as previously described ). Briefly, PBMC were isolated from EDTA-anticoagulated blood using Ficoll-Paque PLUS (GE Healthcare Systems, Uppsala, Sweden) and density centrifugation. Then 1×10 5 PBMC or 2×10 4 cultured CD8 + T cells were used per well in precoated ELISpot PLUS kits (Mabtech USA, Mariemont, OH, USA) according to the manufacturer's instructions. All tests were performed in duplicate or triplicate using individual peptides at 10 μM or serial dilutions 10 μM-100 pM. The positive control, Con A (Sigma-Aldrich, St. Louis, MO, USA), was used at a final concentration of 5 μg/ml. The negative control wells were devoid of any stimulation. The 96-well plates were incubated for 12-18 h at 37°C in 5% CO 2 .
Wells were imaged and counted with an AID EliSpot reader version 4.0 (AID, Strassberg, Germany) and analyzed as described previously ). Background levels were subtracted from each well, and assay results are shown as SFC per 1 × 10 6 PBMC. Responses were considered positive if the mean of the number of SFC was more than 50 spots per million cells and significance was determined using a one-tailed t test where alpha=0.05, and the null hypothesis (H o ): background level≥treatment level.
Intracellular cytokine staining (ICS) assay
SIV-specific CD8 + T-cell lines were used in TNF-α and IFN-γ ICS assays as previously described . Briefly, each test contained 2×10 5 CD8 + T cells and 0.5×10 5 BLCLs or single-allele transfectants. As a positive control, phorbol myristate acetate (1 μg/ml) with ionomycin (2 μg/ml; Sigma-Aldrich) was used. Peptides were used at a concentration of 5 μM or in serial 10-fold dilutions from 5 μM to 500 pM. Approximately 2×10 5 lymphocytegated events were acquired on a BD LSR II (BD Biosciences, San Jose, CA, USA) and analyzed using FlowJo software 9.1 (TreeStar, Ashland, OR, USA). All values were normalized by subtracting the background level staining (negative control of CD8 + T-cell lines in media without stimulation).
Defining epitopes using peptide-specific CD8 + T-cell lines
We cultured CD8 + T-cell lines by incubating 5×10 6 freshly isolated PBMC with the minimal optimal peptide predicted to bind to Mamu-A1*007:01 for 1 to 3 h before washing the cells twice. They were then incubated at 37°C with 5% CO 2 in R-15 [RPMI 1640 supplemented with 15% fetal calf serum, L-glutamine, and antibiotic/antimycotic solution (Hyclone, Logan, UT, USA for all components)] plus 10 ng of recombinant human interleukin-7 (R&D Systems, Minneapolis, MN, USA) per milliliter for 48 h. The R-15 was then supplemented with 100 U of interleukin-2 (NIH AIDS Research and Reference Reagent Program) per milliliter for the length of the culture. Every 7-14 days, the culture was restimulated by the addition of peptidepulsed, gamma-irradiated autologous B-lymphoblastoid cell lines.
After several weeks in culture, we tested the lines for specificity by IFN-γ ELISPOT or by IFN-γ/TNF-α intracellular cytokine staining (ICS) assays with Mamu-A1*007:01 transfectants to verify that immunogenic peptides were restricted by Mamu-A1*007:01.
MHC class I transfectants
MHC class I sequences were cloned into expression vectors from cDNA libraries as described previously (Loffredo et al. 2007a; Burwitz et al. 2009 ). Transient expression of cloned MHC class I cDNA was achieved by electroporation of plasmid DNA into the MHC class I deficient human Bcell line 721.221 (DeMars et al. 1985) . Briefly, 5 μg of plasmid DNA was added to 5×10 6 721.221 cells in 100 μl Nucleofector™ Solution C and electroporated using program G-16 on a Nucleofector I device (Amaxa, Köln, Germany). Transfectants were used 48-72 h postelectroporation. The stable Mamu-A1*007:01 transfectant was created as previously described (Loffredo et al. 2007a) , except for the use of the Nucleofector I device according to the manufacturer's protocols.
MHC class I surface expression on stable and transient MHC class I transfectants was measured by W6/32 antibody surface staining. Immortalized homologous macaque B-cell lines and 721.221 cells were used as positive and negative controls, respectively. Approximately 1×10 5 lymphocyte-gated events were acquired on a BD LSR II (BD Biosciences) and analyzed using FlowJo version 9.1 (Treestar).
Sequencing of plasma viral RNA (vRNA)
We extracted viral RNA from plasma using the QIAGEN MinElute kit (Qiagen, Valencia, CA, USA) or by a guanidine thiocyanate extraction as previously described Friedrich et al. 2007 ). We used the QIAGEN OneStep RT-PCR kit to amplify overlapping regions ∼300-800 nucleotides in length that targeted parts of the SIV mac 239 open reading frames (ORFs) Gag, Pol, Vif, Vpr, and Env. The RT-PCR conditions for all amplicons were as follows: 50°C for 30 min; 95°C for 15 min; 45 cycles of 94°C for 30 s, 53°C for 1 min and 72°C
for 150 s; and 68°C for 20 min. Cycling ramp rates were 2°C per second. Unused primers and nucleotides were removed from the cDNAs using ExoSAP-IT® (USB Corporation).
Both strands of each amplicon were sequenced on a 3730 DNA Analyzer (Applied Biosystems, Carlsbad, CA, USA) using DYEnamic ET Terminators (GE Healthcare) and their respective RT-PCR primers. The sequencing cycling conditions for all amplicons were as follows: 30 cycles of 95°C for 20 s, 50°C for 15 s, and 60°C for 1 min. Sequences were assembled using CodonCode Aligner version 3.7.1 (CodonCode Corporation, Deadham, MA, USA). DNA sequences were conceptually translated and aligned to wild-type SIV mac 239 in MacVector 11.1.1 trial version (MacVector, Inc., Cary, NC, USA).
Ultradeep pyrosequencing of Mamu-A1*007:01-restricted epitopes Ultradeep pyrosequencing of the Mamu-A1*007:01-restricted CD8 + T-cell epitopes was conducted as previously described ). Briefly, cell-free plasma was obtained from EDTA anticoagulated whole blood using Ficoll-Paque PLUS (GE Healthcare) and density centrifugation. Plasma was frozen at −80°C until the time of viral RNA extraction. Viral RNA in the plasma was isolated using the QIAamp MinElute Virus Spin Kit (Qiagen) according to the manufacturer's instructions. Viral RNA was reverse transcribed and amplified using the SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity (Invitrogen, Carlsbad, CA, USA) and MID-tagged primers (454-Life Sciences, Branford, CT, USA) spanning Pol amino acid residues 271-375, 511-602, and 722-825, as well as Vif 46-215 and Vpr 43-102. Amplicons were pooled at equimolar ratios and the final library was diluted to 1×10 6 copies/μl. Emulsion PCR and subsequent bead enrichment was performed at 1.5 copies/bead using the GS FLX Titanium Lib-A emPCR kit per manufacturer's instructions (Roche, Indianapolis, IN, USA). Then 5×10 5 enriched DNA beads were sequenced on a single GS Junior picotiter plate.
Results
Mapping novel epitopes in a vaccinated animal that controls viral replication
We vaccinated animal r97113 with DNA followed by Adenovirus 5 (Ad5) constructs that coded for full-length SIV-Gag, -Tat, -Nef, and -Rev ). This animal had a peak of virus replication of 1.4×10 7 viral RNA copy eq/ml of plasma 5 days after the eighth low-dose intra-rectal challenge with SIV mac 239 (300 TCID 50 per challenge). The animal controlled viral replication for over 100 weeks before viral breakthrough occurred. Since the animal was Mamu-B*008:01-negative and Mamu-B*017:01-negative, we wanted to determine which immune responses were contributing to control of the virus.
We noted novel immune responses in two pools of ten 15-mer peptides. The first pool contained peptides spanning residues 757-807 in SIV mac 239 Pol, while the second spanned residues 1-55 in Vpr. In both cases, the responses were deconvoluted by testing each individual 15-mer within the pool to determine the location of the novel epitope. We then used IFN-γ ELISPOT or ICS to define the minimal optimal epitopes by testing the overlapping 8-, 9-, 10-, and 11-mer peptides contained within the reactive 15-mer (Fig. 1a-c) . Note that for a typical ELISPOT or ICS the peptide concentration is 10 μM (Fig. 1b) , the peptide concentration is 10 μM, whereas in Fig. 1a and c, the peptide concentration is titrated down to less than 1 nM. At 10 μM (10 4 nM), responses are all in a maximal range. Based on a cDNA library of the animal's MHC, we were able to narrow down the potential restricting class I alleles. R97113 had 12 different MHC class I alleles according to the cDNA library. Therefore, we first used a panel of MHC typed B-lymphocyte cell lines (BLCLs) to narrow down which alleles were likely to be involved, and to eliminate those that were not for each peptide. Then we individually transfected seven remaining different alleles into 721.221 cells, which do not express endogenous classical MHC class I molecules on the cell surface, resulting in a panel of seven different transfectants, each expressing a single MHC class I allele. We used autologous BLCL as a positive control and 721.221 cells as a negative control. As a result of our pre-screening with BLCL panels, we determined that Pol 782-789 YL8 could potentially be bound by Mamu-A1*001:01, -A1*007:01, -A*15, -B*012:02, -B*030:01, -B*046, or -B*052:01 (Fig. 2a) , and we used this panel of transfectants as antigen presenting cells by pulsing them with the reactive 15-mer peptide containing Pol 782-789 YL8. Similarly, we determined that Vpr 45-55 NL11 could potentially be bound by Mamu-A1*007:01 or -A2*05:01, and we pulsed these transfectants with the reactive 15-mer peptide containing Vpr 45-55 NL11 (Fig. 2b) . We used the cell line generated from r97113 in each case as a positive control. We were able to determine which allele restricted these two epitopes, and in both cases, the allele was Mamu-A1*007:01 (Fig. 2) . We subsequently determined these two immune responses to be the immunodominant Mamu-A1*007:01-restricted epitopes. We use the term immunodominant here to mean that these two epitopes are presented in most Mamu-A1*007:01-positive rhesus macaques infected with SIV, or vaccinated with these regions of Pol or Nef.
Endogenous Mamu-A1*007:01 peptides
As an initial step to characterize the Mamu-A1*007:01 binding specificity, we eluted and sequenced by mass spectroscopy a total of 42 peptides from Mamu-A1*007:01 (Supplemental Table 2 ). In addition, Edman degradation sequencing of the pooled peptides eluted from Mamu-A1*007:01 provided a motif consistent with the mass spectrometric sequencing of individual peptides (data not shown). The majority of the individual peptides sequenced by mass spectroscopy have a histidine at the P2 anchor residue with a strong preference to be preceded by an asparagine at P1 (Fig. 3) . The C-terminal anchor was dominated by leucine, although a few peptides have a methionine residue at this position (Fig. 3) . When compared to HLA peptide binding motifs, these ligands are most similar to those bound by HLA alleles in the B*27 (Sidney et al. 2008a, b) or B*39 supertypes (Lund et al. 2004) . Alleles in these supertypes are characterized by specificity for ligands with positively charged residues in position 2 and hydrophobic residues at the C terminus. Interestingly, among the alleles associated with the B*27 and B*39 supertypes are B*2705 and B*38:01, both of which have been linked with control of HIV viremia (Hendel et al. 1999; Kaslow et al. 2001; Carrington and O'Brien 2003; Gao et al. 2005; Altfeld et al. 2006; Deeks and Walker 2007; Salgado et al. 2010) . The panel of sequenced ligands was synthesized and tested for their capacity to bind to purified Mamu-A1*007:01 molecules. All but two of the peptides (95%) bound with affinities of 500 nM or better, and half (22/42) bound with affinities of 50 nM or better (Supplemental Table 2 ). Taken together, these data suggest a putative binding motif for Mamu-A1*007:01 and validate the binding assay utilized.
Determination of a quantitative Mamu-A1*007:01 peptide-binding motif using a positional scanning combinatorial peptide library To complement the endogenous ligand sequencing analysis and derive a more detailed quantitative motif for Mamu- . At least 50% of cells had receptor on the surface. The transfectants were pulsed with either the 15-mer peptides used to raise the specific CD8 + T-cell lines, no peptide (data not shown), or an A1*002:01-restricted irrelevant peptide. Peptide-pulsed cells were used in either ICS or ELISPOT assays with peptide-specific CD8 + T cell lines specific for a Polderived 15-mer peptide containing YL8 (a) or a Vpr-derived 15-mer peptide containing NL11 (b). Both cell lines were cultured from animal r97113; autologous BLCLs from this animal were used to check the specificity of the cell line. Peptide-pulsed 721.221 cells were used as a negative control. P/I refers to PMA and ionomycin, which are used as a positive control for inducing cytokine secretion A1*007:01, we next tested the capacity of a positional scanning combinatorial library (PSCL) to bind purified Mamu-A1*007:01 molecules. The binding capacity (IC 50 nM) for each mixture was determined, and then normalized, as described in the "Materials and methods", to generate the resulting Mamu-A1*007:01 matrix shown in Table 1 .
Next, for each position, an average (geometric) relative binding affinity (ARB) was calculated, and then the ratio of the ARB for the entire library to the ARB for each position was derived (Table 2) . This ratio, which we have denominated as the specificity factor (SF), represents the factor by which the normalized geometric average binding affinity associated with all 20 residues at a specified position differs from that of the average affinity of the entire library. As calculated, positions with the highest specificity will have the highest SF value. For Mamu-A1*007:01, the highest SF values were noted for position 2 and the C terminus, with SF of 6.7 and 5.2, respectively; SF for all other positions were found to be <1.6. On this basis, and following previously established criteria (Sidney et al. 2008a ), P2 and the C terminus can thus be identified as the main anchor positions for Mamu-A1*007:01 binding.
In agreement with the pool sequencing derived motif, at position 2 the positively charged residue histidine was the most preferred. The positively charged residue arginine and the polar residue glutamine were also tolerated, with normalized average relative binding (ARB) values of 0.14 and 0.12, respectively. All other residues at position 2 were associated with ARB values <0.04, corresponding to a 25-fold or more decrease in binding affinity, compared to histidine.
At the C terminus, the hydrophobic aliphatic residue leucine was identified as most preferred, followed by the hydrophobic aromatic residue phenylalanine, with an ARB value of 0.51. The hydrophobic residues methionine, isoleucine, and valine were tolerated, with ARBs of 0.14, 0.075, and 0.063, respectively. All other residues at the C terminus were associated with binding capacities more than 25-fold lower than the optimal residue, leucine.
Influences on binding at other positions tended to be minor, reflected by low SF values in the 0.33 to 1.6 range. Defining secondary anchors on the basis of standard deviations (SD), following the rubric previously defined (Sidney et al. 2008a; Loffredo et al. 2009 ), only position 3 is identified as a dominant secondary anchor. Here, the aromatic residue phenylalanine is the most preferred. Small residues alanine, serine, threonine, and valine, and the aromatic residue tyrosine, are all tolerated, with ARBs in the 0.11 to 0.35 range, representing 3-to 10-fold reductions in binding compared to phenylalanine.
In contrast to the pool sequencing data, the PSCL analysis did not identify position 1 as either a primary or dominant secondary anchor position, although asparagine was identified as the optimal residue. With an SD of 2.7, P1 would appear to function as a weak secondary anchor. To examine this further, we also measured the Mamu-A1*007:01 binding capacity of a panel of single amino acid analogs of the Human Ribosomal protein L9 39-48 peptide (sequence NHINVELSL), which was identified above as an endogenously bound Mamu-A1*007:01 ligand (IC 50 13 nM, Supplemental Table 2 ). This panel (data not shown) similarly identified position 2 and the C terminus as the primary anchors, with histidine as the preferred residue in position 2 and leucine and phenylalanine as preferred at the C terminus. While asparagine was again identified as the optimal residue in position 1, this position does not appear to function as a primary anchor, although it may function as an important secondary anchor.
In summary, we used the PSCL to define a detailed motif for Mamu-A1*007:01. This motif is characterized by primary anchor specificity for the positively charged residue histidine in position 2, where arginine and glutamine are also tolerated. A second primary anchor is found at the C terminus, where a preference for the hydrophobic/ aromatic residues leucine and phenylalanine was identified, and methionine, isoleucine, and valine were tolerated. a Single-letter abbreviations for amino acids are used. The percent frequency of specific amino acid residues at each position for eluted ligands is shown. We observed strong preferences at P2 for histidine and the C terminus for leucine, indicating these are the binding anchors. P1 also prefers asparagine, although subsequent analysis indicated it to be a weak secondary anchor. b Frequency of the various lengths of peptides eluted from A1*007:01 Positions 1 and 3 were identified as the most prominent secondary anchors. This motif is in agreement with analyses based on sequencing of eluted ligands, as well as analysis of the binding capacity of a panel of single amino acid substitution analogs of a high affinity Mamu-A1*007:01 binder. A summary cartoon depicting the Mamu-A1*007:01 motif is shown in Fig. 4 .
Identification of SIV mac 239-derived Mamu-A1*007:01-binding peptides To identify SIV-derived Mamu-A1*007:01 restricted T-cell epitopes, we first sought to identify a panel of high affinity Mamu-A1*007:01 binding peptides. PSCL matrices have proven to be an efficient means to identify MHC class I binding peptides (Udaka et al. 1995 (Udaka et al. , 2000 Stryhn et al. 1996; Lauemoller et al. 2001; Peters et al. 2006; Sidney et al. , 2008a Loffredo et al. 2009 ). Thus, for this purpose, we utilized the PSCL-based matrix shown in Table 2 to score all 9-mer peptides in the SIV mac 239 proteome. As before (Sidney et al. , 2008a ), we also adapted the matrix to score peptides of 8, 10, or 11 residues in length. For each size, the peptides scoring in the top 1.5% range (n=50), a selection threshold shown to be associated with the vast majority of epitopes (Moutaftsi et al. 2006; Assarsson et al. 2007; Kotturi et al. 2007; Loffredo et al. 2009 ), were selected for analysis. All 200 peptides were synthesized and tested for their capacity to bind purified Mamu-A1*007:01. The binding affinities of these peptides, as well as several additional other SIV- derived peptides tested in the course of the present study, are provided in Supplemental Table 3 ; all of the binding data will also be submitted to the IEDB (www.iedb.org). As in previous studies, the cutoff for defining a peptide as a candidate binder is an IC 50 value ≤500 nM. This is based on previous work in humans and macaques that have correlated these values to T-cell recognition in vivo (Sette et al. 1994a, b; Allen et al. 1998 ).
In total, 33 of the 200 peptides (17%) bound Mamu-A1*007:01 with an affinity of 500 nM or better (Table 1) . Ten of these peptides bound very strongly (IC 50 ≤50nM). Binders were identified from six different SIV proteins, with the greatest numbers in Env and Pol (10 and 12, respectively). Interestingly, no binders were identified in the Nef, Tat, or Rev proteins.
Several binders, including those with very high affinity (IC 50 <50 nM), were identified for each size examined. However, as expected from the analysis of endogenous ligands, 9-mers were the best overall, both in terms of the percentage of binders (12/50, 24%) and average affinity of the selected peptides (2,520 nM). After 9-mers, 8-mers were the next best (nine binders, average affinity 4,861 nM), followed by 10-mers (six binders, 6,915 nM), and then 11-mers (six binders, 9,906 nM).
Defining six novel epitopes restricted by Mamu-A1*007:01
Next, we examined whether any of the 33 SIV-derived Mamu-A1*007:01 binders would be recognized in SIV mac 239-infected macaques. We used freshly isolated or frozen Values shown represent the average relative binding (ARB) of the corresponding library relative to other pools with the same fixed position.
Values have been normalized to the optimal residue at the corresponding position. ARB values <0.01, representing a 100-fold or greater reduction in binding capacity, relative to the optimal residue at the corresponding position, are represented with a dash ("-"). SD indicates the standard deviation between the ARB of pools at the same position. SF is the specificity factor, which represents the ratio of the average binding of the entire library to the average of pools at the indicated position. Primary anchor positions are defined as those with an SF >2.4 (highlighted with bold font). At the primary anchor positions, preferred anchor residues have been defined as those with an ARB within 5-fold (ARB>0.2) of the optimal residue, and are underlined and highlighted by bold font; tolerated primary anchor residues, defined as those with an ARB between 5-and 25-fold (ARB 0.04-0.2) of the optimal residue, are underlined PBMC from 15 SIV-infected and two vaccinated but uninfected, Mamu-A1*007:01-positive rhesus macaques in IFN-γ ELISPOT assays. In total, the PBMC from these animals secreted IFN-γ in response to 11 of the 33 binders (Table 1) . The magnitude of the responses detected in the ELISPOT assays ranged from 50 to 930 SFCs per 10 6 PBMC. Of the 11 peptides recognized, the number of responding animals ranged from one to six per epitope. Animals r98030 and r97113 responded to the broadest repertoire of binders (six and five, respectively). The highest frequency response was also in r97113, at 930 SFCs per million cells to Vpr 45-55 NL11. This epitope was recognized in five animals, making it the second most frequently targeted after Pol 782-789 YL8.
Of the 11 binders that elicited IFN-γ in ELISPOT, there are two pairs of overlapping peptides that most likely represent a single epitope. Pol 782-791 YF10 contains the minimal optimal Pol 782-789 YL8, while Gag 42-51 DL10 contains the smaller binder Gag 42-50 DL9. We performed functional avidity assays with a minimum of five 10-fold dilutions of these peptides and determined in both cases the shorter peptide to be the minimal optimal (Figs. 1 and 5) . Additionally, we were unable to confirm restriction by Mamu-A1*007:01 for three of the peptides that elicited IFN-γ in the ELISPOT assays. Env 230-240 FL11, Pol 817-825 IL9, and Vif 65-75 SL11 each elicited a response by a single animal (range=70-220 SFC per 1×10 6 ), but we were unable to generate epitope-specific CTL lines with which to confirm the restriction by Mamu-A1*007:01 for the first two responses. For Vif 65-75 SL11, the CTL line that we generated did not secrete IFN-γ to the SL11 peptide in the context of Mamu-A1*007:01; we would hypothesize that this epitope may be restricted by a different MHC class I allele. Thus, we have defined six novel Mamu-A1*007:01-restricted epitopes (Table 3) .
As a negative control, we tested all 33 peptides in two SIV mac 239-infected Mamu-A1*007:01-negative rhesus macaques (r95061 and rhAJ11). No reactivity was observed against any of the peptides (data not shown). Two uninfected Mamu-A1*007:01-positive macaques were also screened in ELISPOT assays to test for cross-reactivity with other non-SIV epitopes. None of the peptides elicited a response from either animal (data not shown).
Mamu-A1*007:01-restricted CD8 + T cells select for viral variation in multiple SIV mac 239 epitopes We isolated virus from plasma of chronically infected Mamu-A1*007:01-positive macaques to look for evidence that these novel CD8 + T-cell responses were capable of selecting for viral variation. We sequenced open reading frames from the SIV proteins Gag, Pol, Vif, and Vpr in the Fig. 4 The binding motif for Mamu-A1*007:01. As determined using eluted ligands, a PSCL binding analysis, and a panel of single amino acid substitution analogs, the motif is summarized to show the main (red fill) and secondary (blue fill) anchor positions. The most preferred residues at the primary anchor positions are indicated by enlarged font. Tolerated anchor residues are also shown. SF values for each position as determined in the PSCL binding analysis, reflecting the relative overall contribution of each position to peptide binding are also shown (yellow fill) The table shows the epitope, the protein from which it is derived, the position of the epitope, and the affinity for Mamu-A1*007:01 regions where we identified epitopes that bind to Mamu-A1*007:01. We compared the amino acid sequences of the novel epitope regions of the virus from the A1*007:01-positive macaques to those from time-of-death sequences previously obtained from 35 Mamu-A1*007:01-negative macaques infected with SIV mac 239 . Amino acid substitutions existed in four of the six epitopes predicted to bind to Mamu-A1*007:01. Two of these are shown in Fig. 6 . Vpr 45-55 NL11 had variation at positions two (histidine to tyrosine), five (asparagine to aspartic acid), seven (histidine to tyrosine), and 11 (leucine to isoleucine) (Fig. 6a) . In total, virus from nine of the 12 Mamu-A1*007:01-positive animals had variation in at least one position within this epitope by Sanger sequencing, while virus from seven of seven animals had variation in a minimum of 15% of sequencing reads across the epitope by ultradeep pyrosequencing. By comparison, only one of the 35 Mamu-A1*007:01-negative animals had any variation within the epitope: virus from r95003 contained the same P5 asparagine to aspartic acid seen in five of the Mamu-A1*007:01-positive animals ). Thus, we detected viral variation at five positions within the epitope, including both primary binding anchor positions, indicating a CD8-mediated selective pressure in Mamu-A1*007:01-positive animals.
In the Pol 782-789 YL8 epitope, we could detect variation in the virus from two animals. Animal r97113 had substitutions in three consecutive positions (four through six) of the epitope (Fig. 6b) . Using ultradeep pyrosequencing of this region, we noticed that the P4 asparagine to aspartic acid change occurred in 67 of 1,361 sequence reads (4.9%), while the P5 valine to alanine change occurred in 68 of 1,361 reads (5%). The P6 lysine to arginine substitution was only present in 1% of reads. The virus we sequenced from this animal was from 258 weeks postinfection, and while there are three changes within this YL8 epitopes. The Vpr epitope has broad and consistent variation at multiple positions within the epitope demonstrating escape in binding anchor positions and TCR-contact residues. The Pol epitope has some variation; however, none of the substitutions has become the dominant circulating species, even after 6 years of replication. This may indicate that this region is under functional constraints epitope, they are all present at low frequencies overall within the circulating virus population. The other animal from which we detected viral variation was r99019. Its virus had a P1 tyrosine to phenylalanine change present in 43% of circulating virus. Additionally, this animal's virus had a P5 valine to isoleucine change present in only 2% of the circulating virus at 109 weeks post-infection. None of the 35 Mamu-A1*007:01-negative animals had any variation within this region of the virus by Sanger sequencing (data not shown). We were able to consistently detect CTL responses to this epitope in both r97113 and r99019, but even after 2 years of virus replication under this selective pressure, the amino acid substitutions that we could detect were all minority species within the animals. Taken together, these data may indicate that this region of the virus is under functional constraints.
Additionally, we detected a single mutation in two other epitopes. Gag 42-50 DL9 in five chronically infected Mamu-A1*007:01-positive macaques contained a single position eight substitution in animal rh2161 from serine to glycine by conventional sequencing. In the Pol 760-769 SL10 epitope, one of the six animals that we investigated with ultradeep pyrosequencing had variation in its virus. Animal r97073 had a position seven valine to isoleucine switch at a frequency of 24.9%. Neither of these regions showed any variation in the 35 Mamu-A1*007:01-negative animals at time of death (data not shown).
While the number of variants is not overwhelming, we are hampered by the low frequency of Mamu-A1*007:01-positive animals in the population, limiting the number of examples we are able to observe. Additionally, we have shown that sequence variation in the epitope has a strong impact on binding affinity to Mamu-A1*007:01 (Table 4 ). The effect of variation on binding affinity, along with the complete lack of variation in these regions in Mamu-A1*007:01-negative animals, indicates that while these mutations are limited in number, they are indeed CTL driven.
Interestingly, in two epitope regions, we did not detect viral variation of any kind. Pol 567-575 TL9 and Vif 145-153 VL9 showed no mutations by Sanger or ultradeep pyrosequencing (data not shown). Indeed, in at least six chronically infected Mamu-A1*007:01-positive animals, despite a minimum of 1,500 sequencing reads across both the Pol and Vif epitopes, we were unable to detect a single mutation that occurred at our minimum cutoff frequency of 1%. These regions of the virus may be under particularly strong functional constraints. Indeed, this Vif region contains a highly conserved motif both among geographically disparate strains of HIV (Stephens et al. 2001 ) and among lentivirus Vif proteins in general (Oberste and Gonda 1992) . CTL specific for epitopes contained within such highly conserved regions may be especially effective at controlling viral replication.
Discussion
It is well established that CTL play a vital role in controlling immunodeficiency virus replication after infection. These T cells are specific for HIV/SIV-derived epitopes presented in the context of specific MHC class I alleles. However, even though we have been using SIVinfected rhesus macaques for more than two decades, we still have incomplete knowledge of the immunogenetics of the macaque model when compared to humans. To date, 650 unique rhesus MHC class I alleles have been identified (IPD database, http://www.ebi.ac.uk/ipd/mhc/nhp/nomen_ mamu.html), and only six alleles from Indian-origin rhesus macaques have been well characterized with regard to their ability to bind peptides derived from SIV and the potential role they may play in control of viral replication. Many of the studied alleles were present at high frequencies, which expanded the group of animals that were useful for vaccine studies. Others have helped define animals that should be excluded from vaccine trials due to the high incidence of spontaneous viral control. Each characterized allele increases our knowledge of this animal model and broadens the pool of animals available for future study.
In this study, we demonstrated that Mamu-A1*007:01 has a binding motif with primary anchor residues at position 2 and the C terminus. Leucine and phenylalanine are the preferred residues at the C terminus although other hydrophobic amino acids can be tolerated. Histidine is the dominant residue at position 2. We also determined that position 3 functions as a strong secondary anchor and that position 1 may also have some influence on Mamu-A1*007:01-peptide binding. This overall motif is similar to the one recognized by HLA alleles classified into the B*27 and B*39 supertypes (Lund et al. 2004; Sidney et al. 2008b) . Indeed, on the basis of primary sequence structure, the B and F pockets of Mamu-A1*007:01, associated with the binding specificity for position 2 and the C terminus, respectively, are identical with those of several B*27 and/or B*39 supertype alleles (Sidney et al. 2008a, b) . We have initiated studies to examine crossreactivity between HLA B*3801, which also has a prominent P2 specificity for H, and Mamu-A1*007:01. B*3801 is of particular interest, as Salgado et al. (2010) have recently demonstrated that it is part of an allele combination (with HLA-Cw*1203) that may have an effect in long-term HIV non-progression. We tested Mamu-A1*007:01 binders for their capacity to bind HLA-B*3801 (Supplemental Table 4 ). About half of these peptides bound HLA-B*3801, including the majority of the epitopes identified in this paper. However, none of the known HLA-B*3801 restricted HIV-derived epitopes bound Mamu-A1*007:01. So, while it is apparent that these two molecules share some binding characteristics, the use of Mamu-A1*007:01-positive animals as an HLA-B*3801 surrogate would be questionable.
We identified 33 SIV-derived peptides with the capacity to bind Mamu-A1*007:01 with high affinity (IC50≤500 nM). Using PBMC derived from SIV mac 239-infected or vaccinated, uninfected Mamu-A1*007:01-positive rhesus macaques, we found that 11 of these peptides, covering nine viral protein regions, could elicit IFN-γ responses in ELISPOT assays. Two of these (Pol 782-789 YL8 and Vpr 45-55 NL11) were previously identified as A1*007:01-restricted epitopes (Sacha et al. 2007 (Sacha et al. , 2010 while four of them represent newly defined epitopes. We were unable to definitively confirm restriction of the other three epitopes by Mamu-A1*007:01.
The SIV-derived peptides utilized in the present study were selected on the basis of predicted relative affinity using a PSCL matrix. This approach has proven successful for identifying Mamu-B*008:01 restricted SIV epitopes ) and as a general means for predicting class I binding peptides (Sidney et al. , 2008a . On the basis of previous observations (Moutaftsi et al. 2006; Kotturi et al. 2007; Loffredo et al. 2009 ), we selected peptides scoring in the top 1.5% range, which would be hypothesized to encompass the vast majority of Mamu-A1*007:01 epitopes. It is possible that additional epitopes may be identified by systematically selecting and testing peptides scoring in lower prediction ranges. However, of the 40 peptides tested in the course of the present study that had PSCL scores in the 1.5% to 50% range, none bound Mamu-A1*007:01 with an affinity of 500 nM or better. Furthermore, and most importantly, five of the six epitopes identified herein had scores in the top 0.8% or better. Thus, it is likely that the current selection process has identified the preponderance of SIV-derived Mamu-A1*007:01-restricted T-cell epitopes.
The phenylalanine discrepancy between the endogenous ligand and PSCL analyses is difficult to speculate upon, but likely reflects the lower frequency of this residue in the endogenous setting compared to L. The eluted ligand analysis will reflect the in vivo "environment" of the cell at the time of analysis, while the binding analysis reflects the in vitro potential of the molecule. Thus, it is also possible that the discrepancy may reflect differences in processing/transport efficiencies associated with the respective residues. This latter hypothesis is perhaps supported by the observation that all of the SIV epitopes identified herein bore L at the C terminus, although it is also notable that L is present with about a 3-fold higher frequency in SIV than F, and is associated with a 2-fold higher average affinity.
Mamu-A1*007:01-restricted CD8 + T lymphocyte responses selected for viral escape. Using both Sanger sequencing and ultradeep pyrosequencing, we observed variation in at least one animal in four of the six regions. In the Vpr 45-55 NL11 epitope, variation was widespread and consistent. While the Pol 782-789 YL8, Gag 42-50 DL9, and Pol 760-769 SL10 epitope variation was less frequent, it is possible that the defined mutations in these epitopes might result in TCR escape. Interestingly, two of the A1*007:01-restricted epitope regions exhibited no variation in circulating virus, even well into the chronic phase in a number of animals. In five of the seven animals we used for the pyrosequencing analysis, the samples were from more than 100 weeks post-infection, and two of them were beyond 250 weeks post-infection. These particular conserved epitopes may be located within regions of the virus that are under severe fitness constraints. Stephens et al. (2001) demonstrated that one of these regions in Vif is highly conserved among geographically diverse isolates of HIV-1. Additionally, Oberste and Gonda (1992) described highly conserved sequence motifs in lentivirus Vif proteins. The SLQXLA motif was present in 34 of 38 of the lentiviruses they examined. This motif is conserved within SIV mac 239, and the Vif 145-153 VL9 epitope that Mamu-A1*007:01 binds contains this exact motif. CTL that target these highly conserved regions may be especially effective at controlling viral replication. In summary, we have characterized, in depth, the peptide binding specificity of the rhesus macaque class I molecule Mamu-A1*007:01. Our studies have led to the identification of six novel SIV-derived CD8 + T-cell epitopes restricted by Mamu-A1*007:01. We have demonstrated that these CD8 + T cells are capable of selecting for viral variation. Additionally, we have described two highly conserved regions of SIV mac 239 targeted by Mamu-A1*007:01-restricted CD8 + T-cell responses. These responses might be useful in testing the hypothesis that CTL that target conserved regions of the virus are more effective at controlling viral replication than those that target variable regions.
